[go: up one dir, main page]

WO2008078424A1 - ベンゾキサゾール誘導体 - Google Patents

ベンゾキサゾール誘導体 Download PDF

Info

Publication number
WO2008078424A1
WO2008078424A1 PCT/JP2007/063350 JP2007063350W WO2008078424A1 WO 2008078424 A1 WO2008078424 A1 WO 2008078424A1 JP 2007063350 W JP2007063350 W JP 2007063350W WO 2008078424 A1 WO2008078424 A1 WO 2008078424A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzoxazole derivatives
conformation disease
composition
conformation
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/063350
Other languages
English (en)
French (fr)
Inventor
Yukitsuka Kudo
Syozo Furumoto
Nobuyuki Okamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2006/325804 external-priority patent/WO2007074786A1/ja
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Priority to US12/520,752 priority Critical patent/US7910579B2/en
Priority to JP2008550970A priority patent/JP5190893B2/ja
Priority to EP07768120A priority patent/EP2103611A4/en
Publication of WO2008078424A1 publication Critical patent/WO2008078424A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　コンフォーメーション病の早期診断に有用なベンゾキサゾール誘導体又はその薬学的に許容される塩もしくは溶媒和物、それを含むコンフォーメーション病診断用組成物及びキット、ならびにコンフォーメーション病治療及び／又は予防用医薬組成物などが本発明により提供される。
PCT/JP2007/063350 2006-12-25 2007-07-04 ベンゾキサゾール誘導体 Ceased WO2008078424A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/520,752 US7910579B2 (en) 2006-12-25 2007-07-04 Benzoxazole derivatives
JP2008550970A JP5190893B2 (ja) 2006-12-25 2007-07-04 ベンゾキサゾール誘導体
EP07768120A EP2103611A4 (en) 2006-12-25 2007-07-04 benzoxazole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPPCT/JP2006/325804 2006-12-25
PCT/JP2006/325804 WO2007074786A1 (ja) 2005-12-26 2006-12-25 コンフォーメーション病診断プローブ

Publications (1)

Publication Number Publication Date
WO2008078424A1 true WO2008078424A1 (ja) 2008-07-03

Family

ID=39562218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/063350 Ceased WO2008078424A1 (ja) 2006-12-25 2007-07-04 ベンゾキサゾール誘導体

Country Status (3)

Country Link
US (1) US7910579B2 (ja)
EP (1) EP2103611A4 (ja)
WO (1) WO2008078424A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5422782B1 (ja) * 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
WO2019054427A1 (ja) 2017-09-14 2019-03-21 第一三共株式会社 環状構造を有する化合物
JP2019123675A (ja) * 2018-01-12 2019-07-25 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
US11291732B1 (en) 2019-11-13 2022-04-05 Aprinoia Therapeutics Limited Compounds for degrading α-synuclein aggregates and uses thereof
US12116364B2 (en) 2018-05-09 2024-10-15 Aprinoia Therapeutics Inc. Heteroaryl compounds and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850111B1 (en) 2012-05-16 2018-11-21 Coloplast A/S Novel polymeric photoinitiators and photoinitiator monomers
CN102936228B (zh) * 2012-11-08 2015-03-11 江苏省原子医学研究所 6-(2-氟乙氧基)-2-甲基苯并噁唑的制备方法
US8951258B2 (en) 2013-03-01 2015-02-10 Warsaw Orthopedic, Inc. Spinal correction system and method
US10736672B2 (en) 2017-05-25 2020-08-11 Warsaw Orthopedic, Inc. Spinal implant system and method
GB201712567D0 (en) 2017-08-04 2017-09-20 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for tau aggregates
CN121100114A (zh) * 2023-05-22 2025-12-09 深圳博芮健制药有限公司 含硫稠环化合物、含其的药物组合物、其制备方法及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000080082A (ja) 1998-09-02 2000-03-21 Kuraray Co Ltd ５−ハロゲノ−２−置換ピリジンの製造方法
JP2001076075A (ja) 1999-09-06 2001-03-23 Toshiba Corp 賛否投票集計システム
WO2003018070A1 (en) * 2001-08-27 2003-03-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
WO2003106439A1 (ja) * 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
WO2004035522A1 (ja) 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
WO2005016888A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
US9605918B1 (en) 2015-11-16 2017-03-28 Pro Mag Mfg., Inc. Rifle magazine with release lever actuator
US9807889B2 (en) 2012-07-30 2017-10-31 Osaka University Method of mounting electronic component to circuit board

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06194780A (ja) * 1992-12-24 1994-07-15 Konica Corp ハロゲン化銀写真乳剤
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
AU712552B2 (en) 1995-05-01 1999-11-11 University Of Pittsburgh Azo compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO1997026919A2 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
JP2000344684A (ja) 1999-03-26 2000-12-12 Bf Kenkyusho:Kk ピロニンｂ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
JP2000344685A (ja) 1999-03-26 2000-12-12 Bf Kenkyusho:Kk アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
WO2001070699A1 (en) 2000-03-22 2001-09-27 Bf Research Institute, Inc. Azure a analogues useful as probes in the diagnostic imaging for diseases due to accumulation of amyloid and compositions for diagnostic imaging containing the analogues
US20030138374A1 (en) * 2000-03-22 2003-07-24 Yukitsuda Kudo Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
JP2002275099A (ja) 2001-03-16 2002-09-25 Bf Kenkyusho:Kk ベンゾシアゾリン環またはベンゾオキサゾリン環を含む化合物による、アミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
WO2002080150A2 (en) 2001-03-28 2002-10-10 Bayer Aktiengesellschaft Optical data medium containing, in the information layer, a dye as a lightabsorbing compound and having a protective covering layer of predetermined thickness
TWI223807B (en) * 2001-03-28 2004-11-11 Bayer Ag Optical data carrier comprising a merocyanine dye as light-absorbent compound in the information layer
JP2004067659A (ja) 2002-06-12 2004-03-04 Bf Kenkyusho:Kk タウ蛋白蓄積性疾患の診断プローブとしてのベンゾイミダゾール環含有化合物
AU2003284492A1 (en) * 2002-12-16 2004-07-09 Bf Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
WO2007074786A1 (ja) * 2005-12-26 2007-07-05 Tohoku University コンフォーメーション病診断プローブ

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000080082A (ja) 1998-09-02 2000-03-21 Kuraray Co Ltd ５−ハロゲノ−２−置換ピリジンの製造方法
JP2001076075A (ja) 1999-09-06 2001-03-23 Toshiba Corp 賛否投票集計システム
WO2003018070A1 (en) * 2001-08-27 2003-03-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
WO2003106439A1 (ja) * 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
WO2004035522A1 (ja) 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
WO2005016888A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
US9807889B2 (en) 2012-07-30 2017-10-31 Osaka University Method of mounting electronic component to circuit board
US9605918B1 (en) 2015-11-16 2017-03-28 Pro Mag Mfg., Inc. Rifle magazine with release lever actuator

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AGDEPPA ET AL., JOURNAL OF NEUROSCIENCE, vol. 21, 2001, pages RC189
BRAAK H.; BRAAK E., AC.TA NEUROPATHOL., vol. 82, 1991, pages 239 - 259
CAI ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, 2004, pages 2208 - 2218
CHANG ET AL., NUCLEAR MEDICINE AND BIOLOGY, vol. 33, 2006, pages 811 - 820
ISHIGURO ET AL., NEUROSC-YLETT., vol. 270, 1999, pages 81 - 84
ITOH ET AL., ANN. NEUROL., vol. 50, 2001, pages 150 - 156
KUDO ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 48, 2007, pages 553 - 561
KUNG ET AL., BRAIN RESEARCH, vol. 956, 2002, pages 202
LE VINE, PROTEIN SCIENCE, vol. 2, 1993, pages 404 - 410
PUCHTLER ET AL., JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 10, 1962, pages 35
PUCHTLER ET AL., JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 77, 1983, pages 431
See also references of EP2103611A4
STEPHENSON ET AL., BIOCONJUGATE CHEMISTRY, vol. 18, 2007
SYNTHESIS, vol. 1, 1984, pages 1 - 28
T. W. GREEN: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
T. W. GREEN: "Synthesis", 1991, JOHN WILEY & SONS
TIPRE ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 47, 2006, pages 345 - 353
WISCHIK ET AL.: "Neurobiology of Alzheimer's Disease", 2001, OXFORD UNIVERSITY PRESS, pages: 103 - 206
YANKNER ET AL., SCIENCE, vol. 245, 1989, pages 417 - 420
ZHANG ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 2005, pages 5980 - 5988

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11667628B2 (en) 2012-12-21 2023-06-06 National Institutes For Quantum And Radiological Science And Technology Compounds for imaging tau proteins that accumulate in brain
WO2014097474A1 (ja) * 2012-12-21 2014-06-26 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
JP5422782B1 (ja) * 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
US12195454B2 (en) 2012-12-21 2025-01-14 National Institutes For Quantum And Radiological Science And Technology Compounds for imaging tau proteins that accumulate in the brain
WO2019054427A1 (ja) 2017-09-14 2019-03-21 第一三共株式会社 環状構造を有する化合物
JP2019123675A (ja) * 2018-01-12 2019-07-25 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
CN111556868B (zh) * 2018-01-12 2023-03-28 上海富吉医疗科技有限公司 放射性核素标记化合物和含有该化合物的显影剂
KR20200109335A (ko) 2018-01-12 2020-09-22 상하이 차트웰 메디컬 인스트루먼트 컴퍼니 리미티드 방사성 핵종 표지 화합물 및 이것을 함유하는 이미징제
CN111556868A (zh) * 2018-01-12 2020-08-18 上海富吉医疗器械有限公司 放射性核素标记化合物和含有该化合物的显影剂
US12116364B2 (en) 2018-05-09 2024-10-15 Aprinoia Therapeutics Inc. Heteroaryl compounds and uses thereof
US11291732B1 (en) 2019-11-13 2022-04-05 Aprinoia Therapeutics Limited Compounds for degrading α-synuclein aggregates and uses thereof
US11642413B2 (en) 2019-11-13 2023-05-09 Aprinoia Therapeutics Limited Compounds for degrading Tau protein aggregates and uses thereof
US12377152B2 (en) 2019-11-13 2025-08-05 Aprinoia Therapeutics Limited Compounds for degrading alpha-synuclein aggregates and uses thereof

Also Published As

Publication number Publication date
EP2103611A4 (en) 2010-06-30
US7910579B2 (en) 2011-03-22
EP2103611A1 (en) 2009-09-23
US20100021385A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2008078424A1 (ja) ベンゾキサゾール誘導体
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
WO2007149030A8 (en) Novel heteroaryl substituted benzoxazoles
UA95267C2 (en) Heteroaryl substituted benzothiazoles
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
IL192150A (en) Use of 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophyll} ethyl-1,3-propanadiol, or its acceptable medical salt or hydrate, for the preparation or treatment of inflammatory bowel disease
WO2008091540A3 (en) 23-substituted bile acids as tgr5 modulators and methods of use thereof
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
WO2007138472A3 (en) Triazolopyridazine derivatives
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
EP1740581A4 (en) ALSHEETS INHIBITORS SUITABLE FOR THE TREATMENT OF ALZHEIMER DISEASE: 2,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
EP1937633B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07768120

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12520752

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008550970

Country of ref document: JP

Ref document number: 2007768120

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE